This in silico investigation fundamentally reshapes the search for AD therapeutics, unveiling a potent new class of multitarget ligand candidates through systematic evaluation against four critical AD proteins: sortilin, clusterin, tau, and amyloid. Here, CLU is linked to Alzheimer disease.